 |
 |
 |
 |
 |
 |
|
||||||||||||||
Select publications
Berry DA et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295(14):1658-67. Abstract
Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353(26):2747-57. Abstract
Coates AS et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2007;25(5):486-92. Abstract
Howell T, on behalf of the ATAC Trialists Group. ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: Completed treatment analysis. San Antonio Breast Cancer Symposium 2004;Abstract 1.
Kennecke H et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 2007;18(1):45-51. Abstract
Mauri D et al. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis. J Natl Cancer Inst 2006;98(18):1285-91. Abstract
Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26. Abstract
| Table of Contents | Top of Page |
Editor:
Neil Love, MD
Interviews
J Michael Dixon, MD
- Select publications
Maura N Dickler, MD
- Select publications
William C Wood, MD
- Select publications
John Mackey, MD
- Select publications
 |
 |
 |
 |
 |
